Drug or treatment

Acalabrutinib clinical trials

• 33Clinical trials
• 40Countries

Newest trials

All recruiting trials (33)

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Acalabrutinib for CLL in routine care in Belarus

  This project will see how well acalabrutinib works and how safe it is for adults with chronic lymphocytic leukemia treated in routine clinical practice in Belarus.

  Recruiting at 3 sites AstraZeneca · Grodno and 3 other locations · NCT07288515

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Acalabrutinib plus R-CHOP as first-line treatment for mantle cell lymphoma in Spain

  This test will see if adding acalabrutinib to standard R-CHOP helps adults in Spain with newly diagnosed mantle cell lymphoma.

  Recruiting at 21 sites Phase 2 AstraZeneca · A Coruña and 21 other locations · NCT07029737

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• Intermittent versus continuous venetoclax with acalabrutinib in CLL/SLL

  This will test whether giving venetoclax intermittently or continuously together with acalabrutinib helps people with previously untreated CLL or SLL.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07014917

• Acalabrutinib with rituximab for untreated mantle cell lymphoma in older adults and lower-risk younger patients

  This trial tests whether combining acalabrutinib and rituximab can produce complete remissions at 12 months in people with untreated mantle cell lymphoma who are elderly or younger with low- to intermediate-risk disease.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06846489

• Using acalabrutinib to treat chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing if acalabrutinib can safely treat people with chronic lymphocytic leukemia or small lymphocytic lymphoma who can't tolerate ibrutinib, while also keeping an eye on their heart health.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06757647

• Acalabrutinib treatment for patients with chronic lymphocytic leukaemia and heart failure

  This study is testing if a new drug called acalabrutinib is safe and effective for people with chronic lymphocytic leukaemia and heart failure compared to other treatment options.

  Recruiting at 18 sites Phase 4 AstraZeneca · Charlotte, North Carolina and 22 other locations · NCT06651970

• Quality of life for people with CLL treated with acalabrutinib in France (PLATON database retrospective analysis)

  This project will test how quality of life changes during the first 12 months in adults with CLL who start acalabrutinib in real-world care in France.

  Recruiting AstraZeneca · Saint-Affrique · NCT06548152

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Combining Lisaftoclax and Acalabrutinib for Newly Diagnosed CLL/SLL

  This study is testing if a new combination of two drugs, Lisaftoclax and Acalabrutinib, can work better than standard treatment for people who have just been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 3 Ascentage Pharma Group Inc. · Bengbu, Anhui and 9 other locations · NCT06319456

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

• Combination therapy for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with mantle cell lymphoma that hasn't responded to previous treatments.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06054776

• Acalabrutinib in first-line CLL in Spain: real-world observation

  This study looks at how patients with chronic lymphocytic leukemia do when they start acalabrutinib as their first CLL treatment in Spain, using real-world data from multiple centers.

  Recruiting at 15 sites AstraZeneca · Almería, Andalusia and 49 other locations · NCT05999877

• Treatment for elderly patients with untreated diffuse large B-cell lymphoma

  This study is testing a new treatment combining acalabrutinib and rituximab for older or frail patients with untreated diffuse large B-cell lymphoma to see if it works better than standard chemotherapy.

  Recruiting at 46 sites Phase 2 AstraZeneca · Berkeley, California and 56 other locations · NCT05952024

• Combination treatment for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT05943496

• Combining Acalabrutinib with R-miniCHOP for older adults with untreated diffuse large B-cell lymphoma

  This study tests if adding Acalabrutinib to the usual treatment for older adults with untreated diffuse large B-cell lymphoma can help them live longer without their cancer getting worse.

  Recruiting at 9 sites Phase 3 Universität des Saarlandes · Homburg, Saarland and 16 other locations · NCT05820841

• Observational study of acalabrutinib for chronic lymphocytic leukaemia in the UK

  This study looks at how well acalabrutinib works for people with chronic lymphocytic leukaemia in the UK by collecting real-life treatment data from their medical records.

  Recruiting at 29 sites AstraZeneca · Aylesbury and 28 other locations · NCT05557695

• Acalabrutinib combined with venetoclax or obinutuzumab for treating chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, acalabrutinib with either venetoclax or obinutuzumab, can help people with chronic lymphocytic leukemia who haven't been treated before by reducing cancer cells in their bone marrow.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05336812

• Using acalabrutinib to prevent relapse in patients with large B-cell lymphoma

  This study is testing if the drug acalabrutinib can help prevent cancer from coming back in patients with large B-cell lymphoma who are at high risk after treatment.

  Recruiting at 2 sites Phase 1/2 Jonsson Comprehensive Cancer Center · Los Angeles, California and 2 other locations · NCT05256641

• Combination treatment for high-risk chronic lymphocytic leukemia

  This study is testing if a new combination of three drugs can help people with high-risk chronic lymphocytic leukemia live longer without their cancer getting worse compared to a combination of two drugs.

  Recruiting at 30 sites Phase 3 German CLL Study Group · Bad Saarow and 29 other locations · NCT05197192

• Combining acalabrutinib and venetoclax for treating tough cases of chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing if combining two medications, acalabrutinib and venetoclax, can help people with tough cases of chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04941716

• Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas

  This study is testing if combining two treatments, acalabrutinib and obinutuzumab, can help people with untreated follicular lymphoma and other slow-growing non-Hodgkin lymphomas feel better and improve their quality of life.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT04883437

• Combination treatment for mantle cell lymphoma

  This study is testing a combination of three drugs to see if they can help people with mantle cell lymphoma that has come back or hasn't been treated yet.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Chicago, Illinois and 2 other locations · NCT04855695

• Retreatment with venetoclax and acalabrutinib for relapsed CLL

  This study is testing if a new combination of venetoclax and acalabrutinib can help people with relapsed chronic lymphocytic leukemia (CLL) achieve better treatment results after their previous therapy.

  Recruiting at 18 sites Phase 2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Brussels and 17 other locations · NCT04523428

• KRT-232 plus acalabrutinib in relapsed/refractory DLBCL or CLL

  This trial tests a new MDM2 inhibitor (KRT-232) together with acalabrutinib to see if the combination helps adults with relapsed or refractory DLBCL or CLL.

  Recruiting at 45 sites Phase 1/2 Kartos Therapeutics, Inc. · Goshen, Indiana and 44 other locations · NCT04502394

• Acalabrutinib, Lenalidomide, and Rituximab for Advanced Follicular Lymphoma

  This phase 2 trial tests whether the combination of acalabrutinib, lenalidomide, and rituximab can control CD20-positive stage III–IV follicular lymphoma in patients who have not yet had systemic lymphoma treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04404088

• Combining acalabrutinib, venetoclax, and possibly obinutuzumab for treating high-risk chronic lymphocytic leukemia

  This study is testing a combination of three medications to see if they can help people with high-risk chronic lymphocytic leukemia feel better and improve their treatment results.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04169737

• Combining acalabrutinib with standard chemotherapy for untreated aggressive B-cell lymphoma

  This study is testing if adding a new drug called acalabrutinib to standard chemotherapy can help people with untreated aggressive B-cell lymphoma get better results.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04002947

• Combination treatment for newly diagnosed CLL patients at high risk of infection

  This study is testing a combination of two cancer drugs to see if it can help newly diagnosed CLL patients who are at high risk of infections stay infection-free before they need chemotherapy.

  Recruiting at 7 sites Phase 2/3 Copenhagen University Hospital, Rigshospitalet · Copenhagen and 6 other locations · NCT03868722

• Combination treatment for indolent B-cell non-Hodgkin lymphoma

  This study is testing a new combination of treatments for people with indolent B-cell non-Hodgkin lymphoma that hasn't responded to previous therapies to see if it can help them.

  Recruiting at 13 sites Phase 1/2 BioInvent International AB · Atlanta, Georgia and 26 other locations · NCT03571568

• Acalabrutinib with or without Obinutuzumab for early-stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  This study is testing whether a new drug called acalabrutinib, alone or with another drug called obinutuzumab, can help people with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT03516617

Quick answers

How many clinical trials of Acalabrutinib are recruiting right now?

33, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 40 countries. The most sites are in United States (22 trials), Spain (8 trials), United Kingdom (7 trials), Poland (6 trials), Czechia (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 3: 6, Phase 1/2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →